Exelixis Inc. said Oct. 10 its cabozantinib drug performed better against sunitinib in treating advanced kidney cancer, prompting the company to plan an application for the treatment in the U.S.
Results from randomized phase two trial with patients suffering from previously untreated advanced renal cell carcinoma showed cabozantinib decreasing rate of disease progression or death by 31% when compared to sunitinib, which is marketed by Pfizer Inc
Exelixis and partner Ipsen will jointly host a live webcast at 1 p.m. ET on Oct. 10 to discuss the study and its data.